1.Thies W, Bleiler L: Alzheimer’s Association 2011 Alzheimer’s disease facts and figures. Alzheimers Dement 2011, 7:208–244.
2.Kasai M, Nakamura K, Meguro K: [Alzheimer’s disease in Japan and other countries: review of epidemiological studies in the last 10 years]. Brain Nerve 2010, 62:667–678.
3.Jitapunkul S, Kunanusont C, Phoolcharoen W, Suriyawongpaisal P: Prevalence estimation of dementia among Thai elderly: a national survey. J Med Assoc Thai 2001, 84:461–467.
4.Jitapunkul S, Chayovan N, Kespichaywattana J: National policies on ageing and long-term care provision for older persons in Thailand. In Ageing and Long-Term Care: National Policies in the Asia-Pacific. Edited by Phillips DR, Chan ACM. Singpapore: Bestprint Printing Co.; 2002: 181–213
5.Evans JG, Williams TF, Beattie BL, Michel J-P, Wilcock GK: Oxford Textbook of Geriatric Medicine. Great Clarendon Street, Oxford OX2 6DP: Oxford University Press; 2000.
6.Mufson E, Counts S, Perez S, Ginsberg S: Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother 2008, 8:1703–1718.
7.Mesulam M: The cholinergic lesion of Alzheimer’s disease: pivotal factor or side show? Learn Mem 2004, 11:43–49.
8.Boccardi V, Baroni M, Smirne N, Clodomiro A, Ercolani S, Longo A, Ruggiero C, Bruni AC, Mecocci P: Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer’s Disease: A ”Real World” Study. J Alzheimers Dis 2017, 56:239–248.
9.Wattmo C, Wallin AK, Londos E, Minthon L: Predictors of long-term cognitive outcome in Alzheimer’s disease. Alzheimers Res Ther 2011, 3:23.
10.Rudolph J, Salow M, Angelini M, McGlinchey R: The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008, 168:508–513.
11.Tune L: Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001, 62 Suppl 21:11–14.
12.Mintzer J, Burns A: Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000, 93:457–462.
13.Johnell K, Fastbom J: Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging 2008, 25:871–877.
14.Andrade C: Anticholinergic Drug Exposure and the Risk of Dementia: There Is Modest Evidence for an Association but Not for Causality. J Clin Psychiatry 2019, 80.
15.Carrière I, Fourrier-Reglat A, Dartigues J, Rouaud O, Pasquier F, Ritchie K, Ancelin M: Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009, 169:1317–1324.
16.Fox C, Livingston G, Maidment ID, Coulton S, Smithard DG, Boustani M, Katona C: The impact of anticholinergic burden in Alzheimer’s dementia-the LASER-AD study. Age Ageing 2011, 40:730–735.
17.Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F: Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging 2015, 10:1457–1466.
18.Ah YM, Suh Y, Jun K, Hwang S, Lee JY: Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: A population-based study. Basic Clin Pharmacol Toxicol 2019, 124:741–748.
19.Picton JD, Marino AB, Nealy KL: Benzodiazepine use and cognitive decline in the elderly. Am J Health Syst Pharm 2018, 75:e6-e12.
20.Roux B, Sirois C, Simard M, Gagnon M-E, Laroche M-L: Potentially inappropriate medications in older adults: a population-based cohort study. Fam Pract 2019.
21.Andre L, Gallini A, Montastruc F, Montastruc J-L, Piau A, Lapeyre-Mestre M, Gardette V: Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. Eur J Clin Pharmacol 2019, 75:1631–1644.
22.Committee TTBF: Thai Mental State Examination (TMSE) Siriraj Med J 1993 45 359–374
23.Wangtongkum S, Sucharitkul P, Silprasert N, Inthrachak R: Prevalence of dementia among population age over 45 years in Chiang Mai, Thailand. J Med Assoc Thai 2008, 91:1685–1690.
24.Boustani M, Campbell N, Munger S, Maidment I, Fox C: Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008, 4:311–320.
25.Lee EK, Lee YJ: Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia. Int J Clin Pharm 2013, 35:711–718.
26.Chatterjee S, Bali V, Carnahan RM, Chen H, Johnson ML, Aparasu RR: Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. J Am Geriatr Soc 2016, 64:1492–1497.
27.Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE: Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer’s disease patients. Geriatr Gerontol Int 2019, 19:913–917.
28.Rockwood K, Walsh R, Martin E, Darvesh S: Potentially procholinergic effects of medications commonly used in older adults. Am J Geriatr Pharmacother 2011, 9:80–87.
29.Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T: Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA network open 2019, 2:e190828-e190828.
30.Puustinen J, Nurminen J, Vahlberg T, Lyles A, Isoaho R, Räihä I, Kivelä S-L: CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. Dement Geriatr Cogn Dis Extra 2012, 2:57–68.
31.Grossi CM, Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Campbell N, Boustani M, et al: Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatr 2019, 19:276.
32.Törmälehto S, Martikainen J, Bell JS, Hallikainen I, Koivisto AM: Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer’s disease over a three-year period: Kuopio ALSOVA study. Int Psychogeriatr 2017, 29:1723–1733.
33.Panel BtAGSBCUE: American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2019, 67:674–694.